1. Generation of glycan-specific nanobodies.
- Author
-
Khilji SK, Goerdeler F, Frensemeier K, Warschkau D, Lühle J, Fandi Z, Schirmeister F, Chen ZA, Turak O, Mallagaray A, Boerno S, Timmermann B, Rappsilber J, Seeberger PH, and Moscovitz O
- Subjects
- Antibodies, Fucose, Humans, Immunization, Polysaccharides, Single-Domain Antibodies chemistry
- Abstract
The development of antibodies that target specific glycan structures on cancer cells or human pathogens poses a significant challenge due to the immense complexity of naturally occurring glycans. Automated glycan assembly enables the production of structurally homogeneous glycans in amounts that are difficult to derive from natural sources. Nanobodies (Nbs) are the smallest antigen-binding domains of heavy-chain-only antibodies (hcAbs) found in camelids. To date, the development of glycan-specific Nbs using synthetic glycans has not been reported. Here, we use defined synthetic glycans for alpaca immunization to elicit glycan-specific hcAbs, and describe the identification, isolation, and production of a Nb specific for the tumor-associated carbohydrate antigen Globo-H. The Nb binds the terminal fucose of Globo-H and recognizes synthetic Globo-H in solution and native Globo-H on breast cancer cells with high specificity. These results demonstrate the potential of our approach for generating glycan-targeting Nbs to be used in biomedical and biotechnological applications., Competing Interests: Declarations of interests O.M. and P.H.S. are co-founders of Tacalyx GmbH, where P.H.S. is a board member. O.M. and P.H.S. have a significant financial interest in the company and field a patent for the Nbs described in this manuscript (EP3799881A1)., (Copyright © 2022 Elsevier Ltd. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF